Background Studies of primary total joint arthroplasty (TJA) show a correlation between hospital volume and outcomes; however, the relationship of volume to outcomes in revision TJA is not well studied. Questions/purposes We therefore asked: (1) Are 90-day readmissions more likely at low-volume hospitals relative to high-volume hospitals after revision THA and TKA? (2) Are in-hospital and 90-day complications more likely at low-volume hospitals relative to high-volume hospitals after revision THA and TKA? (3) Are 30-day mortality rates higher at low-volume hospitals relative to highvolume hospitals after revision THA and TKA? Methods Using 29,948 inpatient stays undergoing revision TJA from 2008 to 2014 in the Statewide Planning and Research Cooperative System (SPARCS) database for New York State, we examined the relationship of hospital revision volume by quartile and outcomes. The top 5 percentile of hospitals was included as a separate cohort. Advantages of the SPARCS database include comprehensive catchment of all cases regardless of payer, and the ability to track each patient across hospital admissions at different institutions within the state. The outcomes of interest included 90-day all-cause readmission rates and 30-and 90-day reoperation rates, postoperative complication rates, and 30-day mortality rates. The initial cohort that met the MS-DRG and ICD-9 criteria consisted of 30,354 inpatient stays for revision hip or knee replacements. Exclusions included patients with a missing patient identifier (n = 221), missing admission or discharge dates (n = 5), and stays from hospitals that were closed during the study period (n = 180). Our final analytic cohort comprised 29,948 inpatient stays for revision hip and knee replacements from 25,977 patients who had nonmissing data points for the variables of interest. Outcomes were adjusted for underlying hospital, surgeon, and patient confounding variables. The analytic cohort included observations from 25,977 patients, 138 hospitals, 929 surgeons, 14,130 revision THAs, 11,847 revision TKAs, 15,341 female patients (59% of cohort). Each author certifies that neither he or she, nor any member of his or her immediate family, have funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. Clinical Orthopaedics and Related Research® neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA approval status, of any drug or device before clinical use. Each author certifies that his or her institution waived approval for the reporting of this investigation and that all investigations were conducted in conformity with ethical principles of research.